Definitive Healthcare Corp. (NASDAQ:DH) Receives Average Recommendation of "Reduce" from Analysts

Shares of Definitive Healthcare Corp. (NASDAQ:DH - Get Free Report) have received a consensus recommendation of "Reduce" from the ten brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $5.10.

Several research analysts have recently issued reports on the stock. BTIG Research lowered shares of Definitive Healthcare from a "buy" rating to a "neutral" rating in a research note on Friday, May 9th. The Goldman Sachs Group lifted their price objective on shares of Definitive Healthcare from $3.00 to $3.40 and gave the stock a "neutral" rating in a research note on Monday, May 12th. Wall Street Zen lowered shares of Definitive Healthcare from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Barclays reduced their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research note on Monday, March 3rd.

Definitive Healthcare Trading Up 1.5%

Shares of NASDAQ DH traded up $0.05 during mid-day trading on Wednesday, hitting $3.32. The company's stock had a trading volume of 1,286,317 shares, compared to its average volume of 815,085. The stock has a market cap of $493.49 million, a price-to-earnings ratio of -1.07, a price-to-earnings-growth ratio of 4.06 and a beta of 1.48. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.49 and a quick ratio of 2.49. Definitive Healthcare has a one year low of $2.15 and a one year high of $6.27. The company's fifty day simple moving average is $2.86 and its 200-day simple moving average is $3.76.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. The company had revenue of $59.19 million for the quarter, compared to analyst estimates of $56.20 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. The company's revenue for the quarter was down 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.08 EPS. On average, sell-side analysts anticipate that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

Institutional Trading of Definitive Healthcare

Hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC raised its holdings in Definitive Healthcare by 3,652.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock worth $29,000 after buying an additional 6,794 shares during the period. Bayesian Capital Management LP acquired a new stake in Definitive Healthcare during the 4th quarter worth approximately $41,000. Ieq Capital LLC acquired a new stake in Definitive Healthcare during the 4th quarter worth approximately $51,000. Hsbc Holdings PLC acquired a new stake in Definitive Healthcare during the 1st quarter worth approximately $52,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Definitive Healthcare during the 4th quarter worth approximately $54,000. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.